Post by
subaru1 on Apr 03, 2023 1:36pm
Now
We know the dilution for Vivo acquisitions, 107,930,564 more share on the market. Since Mr. Pidduck is Medipharm CEO the stock went from $0,16 to $0,75 down more than 50%. the appeal on Hexo is due end of May. Now Mr Pidduck it is time to give a boost to that company you have change the orientation of the company the mix product sold the Australian business buy Vivo these are your decision, hopefully you will get rid of Vivo management, as you were saying in the conf. call 1 major drup development would change the company totally but this can take years so something has to happen in the meantime.
Comment by
Stonksonlyup90 on Apr 03, 2023 1:54pm
Significant reduction in cash burn and moving in the right direction toward profitability. We are on the right track with Pidduck, idk what you're spewing.